Pancreatic Cancer Therapeutics in Major Developed Markets expected Growth $2.92 billion in 2021

ResearchMoz added Latest Research Report titled " Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape " to it's Large Report database.

Pancreatic Cancer (PC) is a disease predominately of the elderly with ~75% of PC cases being diagnosed in patient’s over 75 years old. PC proliferates rapidly, is asymptomatic at its earliest stages and when symptoms do present themselves they are non-specific. There are currently no early detection methods in use for PC. Currently the best option for patient survival is resection which can triple five year survival rate to 15% compared to the unresectable stages of PC. Regrettably ~83% of patients present with advanced unresectable disease and patient prognosis is extremely poor. The majority of patients ultimately develop resistant disease, for whom treatment options have historically been limited, with treatment involving fluorouracil as a monotherapy or used in a combination therapy being standard. The recent approval of Onivyde for gemcitabine refractory disease in 2015 has improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=499497

The current late-stage drugs in development for PC address this clinical need; however, results so far have been limited in their efficacy, with none demonstrating clinically transformative efficacy or safety. As a result, the growth in PC prevalence as a result of a global aging population, increasing diabetes and obesity prevalence is expected to be the key driver of this market throughout the forecast period.

Scope

Global revenues for the PC market are forecast to rise at a moderate CAGR of 7.6% from $1.746bn in 2014 to $2.92bn in 2021.

•     What factors are driving the market growth?
•     How can the factors limiting growth be overcome in the future?

    The variation in mechanism of action has shifted away from the traditional chemotherapies, which dominate the marketed products, but account for only 7% of the pipeline. 44% of the pipeline are drugs inhibiting signal transduction.

•     What are the dynamics of the remaining 49% of the pipeline?
•     How does this reflect the need for novel targeted therapies?

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9

2 Introduction 11
2.1 Disease Introduction 11
2.2 Epidemiology 11
2.3 Symptoms 12
2.4 Risk Factors 13
2.4.1 Age 13
2.4.2 Smoking 13
2.4.3 Obesity 13
2.4.4 Diet 13
2.4.5 Inherited Mutations 14
2.4.6 Chronic Pancreatitis 14
2.4.7 Diabetes 14
2.4.8 Infectious Diseases Risk Factors 14
2.4.9 Precursor Lesions 15
2.5 Pathophysiology 15
2.5.1 Somatic Mutations 15
2.6 Disease Stages 17
2.7 Diagnosis 18
2.8 Disease Prognosis 19
2.9 Treatment Algorithm 19
2.9.1 Adjuvant Therapy, Resected Cancer 20
2.9.2 First-Line Treatment, Unresectable 21
2.9.3 Second-Line Treatment, Unresectable 22

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG